Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer
Executive Summary
Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a meeting on the drug after a large number of comments were received following the institute’s initial knockback.